Galway based medtech company Aerogen is collaborating on the delivery of the world’s first inhalable COVID-19 vaccine.
Aerogen have signed a deal with Tianjin based company CanSinoBIO, to utilise Aerogen’s vibrating mesh aerosol drug delivery technology.
This will be the delivery system for CanSinoBIO’s Convidecia COVID-19 vaccine, where the aerosolised vaccine is directly inhaled via a cup dispenser into the patient’s airway.
John Power, Aerogen CEO & Founder said “The world has an urgent need for an effective, low cost, globally scalable and globally accessible solution to mass vaccination.”
“The pioneering development undertaken by Aerogen and CanSino has resulted in a system that meets all these requirements and with a capacity to vaccinate in the billions.”
Aerogen said that Phase 3 clinical trials conducted by CanSinoBIO show that their vaccine has a 95.47% efficacy at preventing severe disease within two weeks of the single dose vaccine.
CanSinoBio is preparing an application for commercial authorisation in China. Further clinical trials are in the process of being prepared for other countries.
Dr. Xuefeng YU, Chairman and Chief Executive Officer of CanSinoBIO commented; “Our partnership with Aerogen started in 2013 and for almost a decade, we’ve been advancing the possibility of aerosol drug delivery.”
“The innovative development on the inhaled delivery of COVID-19 vaccine is the testimony
of our collaborative efforts.”
“It is demonstrated that the aerosolised vaccine can stimulate mucosal immunity and significantly reduce the risk of transmission, which could be a solution to rapidly build mass
immune protection and accelerate the end of the pandemic.”
Commercial terms of the partnership have not been disclosed.
